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a b s t r a c t
Palliative care is an approach aimed at improving the quality of life of patients (and their
families) faced with a life-threatening condition. Chronic heart failure (CHF) is a progressive
disease with increasing incidence and prevalence. Despite (or perhaps, because of) all
the advances in medicine, CHF remains one of the leading causes of death. Even with the
availability of numerous prognostic tools, an estimate of the course and outcome of a CHF
patient continues to pose a challenge. As a result, palliative care should be initiated early and
provided in parallel with curative treatment. The cornerstone of palliative care is communi-
cation based, mainly, on listening to the patient, telling the patient their unfavorable
diagnosis, and therapeutic dialog. Drug therapy is provided in an effort to alleviate the
symptoms. Non-pharmacological options of improving the quality of life of the patient
include nutritional care, rehabilitation and, possibly, treatment of sleep apnea. Deactivation
of the implantable cardioverter/deﬁbrillator should also be considered as an option. Last but
not least, the attending physician should focus on the psychological and spiritual needs of
the patient. Palliative care in cardiology poses a major challenge to all members of teams
caring for the CHF patient not only over the last weeks of their lives, but during their entire
course of treatment.
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Introduction
Cardiac and cancer patients alike face numerous physical,
psychological, and social problems. Due to the advances in
modern medicine, the incidence of CHF is on the increase and
its mortality continues to be high and comparable with those
of the most common malignancies [1]. Symptoms deteriorat-
ing the quality of life occur in CHF patients at the same rate as
in cancer patients [2]. Despite all the advances in CHF
management, the ﬁnal stage of the disease is associated with
very poor quality of life [3]. Generally, the term palliative care
refers to an approach designed to improve the quality of life of
patients (and families thereof) faced with a life-threatening
condition [4]. All these facts taken together, there is logically
an effort to implement palliative approaches also in cardiolo-
gy. However, the concept of palliative care in cardiology has
not been clearly deﬁned. To date, no methodology of palliative
care has been developed, there are no large randomized trials
providing the evidence base for current cardiology, many
cardiologists actually do not think in the context of palliative
Tradional transion between curave and palliave care
Curave approach aimed at treang 
the disease or prolonging life
Palliave care 
is focused on 
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control and 
quality of life
Early integraon model of palliave care
Curave approach aimed at treang 
the disease or prolonging life
Palliave care is focused on 
symptom control and quality of life
diagnosis death
deathdiagnosis
Fig. 1 – Mode of care integrating palliative and curative
approaches.
Adapted from [45].
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willingness to communicate about end-of-life issues, patients'
feelings and preferences. Some reports have documented an
astonishingly low level of agreement between the views of the
patient and his physician (cardiologist) regarding priorities for
care toward the end of life [5,6].
When exploring the issue of palliative care in cardiology, it
is worthwhile to highlight some aspects distinguishing
palliative care in cardiology from that in oncology. It is a
well-known fact that the end stage of the heart failure patient
may be largely different [7]. In addition to the underlying
disease, other factors signiﬁcantly affecting the quality of life
of the cardiac patient include their often older age, poly-
pharmacy, and comorbidities. Likewise, in some patients, the
side effects of commonly used drugs may pose a problem
bigger than the disease per se. Multiple episodes of heart failure
progression experienced by the patient and perceived by their
family members with a gradually waning response to therapy
are often in stark contrast with their expectations and absence
of an explanation why this is so. In oncology, the limitations of
therapeutic options are almost generally anticipated, and
different rates of disease progression to death are accepted.
Given the impressive strides in reducing morbidity and
mortality rates, the situation is just the opposite in cardiology,
a specialty associated – among lay people – with triumph of
medical science over disease and patient recovery, all this
despite the fact that cardiovascular disease remains the
number one killer in Europe (42% of males, 52% of females) [8].
Prognostic stratiﬁcation and optimal timing of
palliative care initiation
Establishing the prognosis of an individual heart failure
patient, that is, estimating the time until their death at
various stages of the disease is indeed a major challenge. In
this context, the question naturally arises as to the timing of
palliative care initiation. To date, up to 300 potential
prognostic markers have been investigated. A rough estimateof prognosis can be based on the NYHA classiﬁcation
combined with some biochemical markers (B-type natriuretic
peptide, natremia), and exercise capacity or cardiac output
measurement. Several comprehensive tools and scoring
systems have been developed and tested to estimate the
prognosis of heart failure patients; these include the Seattle
Heart Failure Score [9] available online at (http://depts.
washington.edu/shfm/). Other scoring systems such as the
CardioVascular Medicine Heart Failure (CVM-HF) index [10] or
that employed in the EFFECT trial [11] have incorporated
comorbidities into the prognostic scheme. Still, in most cases,
the presence of progressive renal insufﬁciency, cachexia, and
increased diuretic use serve as reliable markers of a dismal
prognosis in elderly and polymorbid patients [12]. While an
estimate of survival of an individual patient remains difﬁcult
despite the above options, the following situations may lead to
the decision to initiate palliative care: repeated episodes of
heart failure over the last 6 months despite optimal manage-
ment, occurrence of malignant arrhythmias, frequent need for
intravenous diuretics or their continuous administration,
long-term poor quality of life, refractory NYHA IV class
symptoms, and signs of cardiac cachexia [13]. Recently, there
has been general consensus that palliative care should
optimally be initiated in parallel with full curative therapy
with a gradual increase in the proportion of palliative care and
adequate decrease in curative therapy toward the end of life,
that is, both approaches run in parallel. The previous strategy
whereby curative therapy is replaced by palliative care several
weeks before death is being discarded (Fig. 1). The current
integrating strategy seems to be the most advantageous
particularly because many heart failure patients do not show
major deterioration of their quality of life in its ﬁnal stages [14].
Communication
Communication is the cornerstone of palliative care. Unlike
oncologists, cardiologists ﬁnd themselves in a much more
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virtually no training in communication skills allowing them to
address issues related to the diagnosis of an incurable disease
(which heart failure doubtless is), the process of dying, and the
therapeutic options available in the individual stages of the
disease. It is not usual to listen to a patient's preferences. At
this point, it should be mentioned that communication with
the patient is as important as communication with his family
and/or the caregiver. All physicians and nurses alike taking
care of heart failure patients should be prepared, if asked by
the patient or his family, for discussion about the nature of the
disease and the process of dying. Still, what is really needed is
a more proactive approach by the attending physician toward
either party involved as, though every effort is made to
improve a patient's functional ﬁtness and defer death, it is
critical to talk to the patient and his family – once the diagnosis
of heart failure has been established – about the progressive
nature of the disease which will eventually impair the quality
of life and survival. Such an approach, whilst helping to
optimally ﬁght the disease immediately after diagnosis, will
also prevent experiencing distress later should symptoms
recur and progress gradually [15].
Besides essential information about body weight self-
monitoring and the possibility of adjusting diuretic doses,
communication in palliative care plays other roles. First and
foremost, it is what is referred to as ‘‘active listening‘‘, which
certainly does not mean only a properly taken patient's
medical history. Of equal importance is knowledge of the
patient's attitude toward his disease, understanding his fears
and concerns, his list of life priorities, and what he is actually
worried about. The aim of this process is to learn whether the
patient and family understand the implications of the disease
[16].
A most speciﬁc, dreadful task is to convey the unfavorable
information about the presence of an incurable progressive
disease to the patient (and subsequently, if agreed, to theirTable 1 – Elements of communication about a grim prognosis; 
Conversation with ‘‘bad news’’ Proper timing of deliver
him/her; and proceed a
Ask-Tell-Ask Ask the patient what he
Correct any misunderst
Tell the patient your in
Ask if there are any que
Simple, honest language, simple statistics Explain medical terms, 
percentages (preferably
Describe the multifaceted nature of reality Describe the chances of
Hope for the best, plan for the worst
(‘‘Not only . . ., but also . . .’’)
Ask the patient what he
Tell the patient what w
Plan for death or anoth
Normalize uncertainty Acknowledge we canno
Partner and plan Tell the patient you and
cope with difﬁcult situa
Set the length of life in a broad range Set a broad range of ‘‘m
Empathy Name your emotions (‘‘
the patient or such he/s
is normal to feel anger,
Follow-up Summarize the plan anfamily and/or caregivers). Every clinician taking care of a heart
failure patient should receive basic training in delivering the
bad news to the patient, and discussing facts about the end of
life along the same lines as in oncology. The key aspects of
communication are summarized in Table 1.
A third major feature of mutual communication in
palliative care is therapeutic dialog. Occasionally, the patient
is not asked about the way he would like to be managed in the
given stage of his disease at all, or his views are simply
disregarded. During the course of treatment, the patient
should be repeatedly updated about the reasons for, and
potential implications of his current therapy and alternative
options. At the same time, a patient with a reasonable level of
information should be able to refuse any of the procedures,
particularly at a later stage of the disease. Thus, due attention
should be given to relevant issues such as, for example, a
patient's decision not to have cardiac surgery, attempted
resuscitation and stop or, possibly, refuse treatment with the
implantable cardioverter/deﬁbrillator [17].
Discussion about a patient's attitude to cardiopulmonary
resuscitation (CPR) is just another uneasy task for the clinician
and one associated with concern about upsetting the patient.
However, as the SUPPORT trial clearly showed that the attitude
of patients toward CPR is inconsistent, discussion about one's
end of life should not only be initiated but, also, encouraged
repeatedly to possibly allow for revision [6].
Optimization of contact with the family and care givers in
palliative care is of utmost importance. It is just these
individuals who will remember the quality of life of their
loved one over the last months and weeks of life, and the way
he or she was dying and, also, the way he or she was being
treated in a most emotion-laden period of time. This is also a
period of time when a well-trained nurse may prove simply
invaluable to the physician as she is able to repeatedly educate
the patient and family on the above topics and, possibly,
obtaining answers to questions she is unable to handle. Theadapted from [46].
ing sad and unexpected news; warn the patient we have bad news for
s follows.
 actually knows about his/her disease.
anding.
formation.
stions and provide clariﬁcation if needed.
use plain language and avoid euphemisms, statistical data and
 ‘‘one in ﬁve patients. . .’’).
 both death and cure as well as a chance to defer death.
/she hopes for.
e can ideally both hope for in medical terms.
er bad outcome ‘‘if things do not go they way we hope for’’.
t know for sure ‘‘. . .like many things in life. . .’’
 (your team) will do our best to help the patient and his/her family to
tions.
onths to years’’ and allow for error at either end.
I am sad’’) and identify the emotions either explicitly expressed by
he can reasonably experience (‘‘I know it comes as a surprise . . .’’, ‘‘it
 fear . . .’’)
d set an appointment to follow-up on plans and his/her status.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 9 – e 4 4e42attitude toward communication is most cogently summarized
in the American Heart Association scientiﬁc guidelines stating
that ‘‘. . .difﬁcult discussions now will simplify difﬁcult
decisions in the future’’ [18].
Palliative care and medical therapy
As large clinical trials searching for optimal algorithms in the
treatment of heart failure have mostly excluded elderly and
polymorbid patients or those in the end stage of a disease, no
consistent data are available as to managing these cases.
There is consensus that standard management of heart failure
should be provided in cardiology almost until the last moment
unless the patient, after being thoroughly informed, has
refused to accept any of the options available. Medication
should be revised on a regular basis. In cases showing clinically
obvious signs of the end stage of the disease, it is appropriate
to individualize management and possibly withdraw some of
the drugs that could potentially deteriorate the quality of life at
a time when no one can reasonably expect the prognosis will
improve. Here again, the care giver should see the model
shown in Fig. 1.
The most common symptoms in a large proportion of
patients with advanced chronic heart failure include dyspnea,
pain, cough, edema and fatigue as well as low exercise
tolerance, anxiety, depression, sleeplessness, nausea, loss of
appetite, weight loss, constipation, and other problems often
refractory to standard therapy [19–21]. Regular thorough
assessment of symptoms may not only help focus on
procedures to alleviate these problems, but also to estimate
the patient's prognosis.
The mainstay of dyspnea management throughout the
course of the disease is standard therapy consistent with
current guidelines [22,23]. Should dyspnea persist despite
maximum tolerated medical therapy in the end-of-life stage,
morphine administration should be considered. Morphine
should hypothetically reduce respiratory work and prevent
premature respiratory muscle weakness, and a decreased
sense of difﬁculty breathing due to morphine action on opioid
receptors in the brain and lungs; the anxiolytic-like effect of
morphine should also not be disregarded [24–26]. Its side
effects may include constipation. While there is no generally
accepted morphine administration protocol based on data
from clinical trials and divergent opinions persist, it is
empirically assumed that therapy should be initiated in a
manner similar to that in the management of otherwise
uncontrollable cancer-related pain, with further dose titration
guided individually by the clinical outcome. A meta-analysis of
18 trials demonstrated a signiﬁcant beneﬁcial effect of oral or
parenteral opiates on dyspnea relief [27]; opiate administra-
tion over periods as long as several months seems to be both
effective and safe [28].
Quite often, patients with chronic heart failure will complain
of non-speciﬁc pain, not always clearly related to heart failure.
As a result, targeted questions and effective pain control are just
another option for improving the quality of life [29,30]. However,
when selecting the active substance, it is imperative to avoid
the use of non-steroidal anti-inﬂammatory drugs increasing
sodium and water retention.Non-pharmacological therapy
Together with symptoms and overall psychological ill-being,
poor functional ﬁtness levels and reduced mobility constitute
the main factors signiﬁcantly deteriorating the quality of life of
heart failure patients [31]. The decrease in functional ﬁtness is
due partly to generalized muscular atrophy or directly to
cardiac cachexia associated with loss of adipose tissue. These
conditions are caused by neuroendocrine and immunological
processes, not infrequently combined with loss of appetite and
malabsorption in the presence of gastrointestinal tract
congestion or as a result of side effects of the drugs used to
treat comorbidities. Cardiac cachexia not only deteriorates the
quality of life, it worsens the prognosis [32].
In patients with inadequate oral intake, enteral nutrition by
means of oral nutritional supplements or tube feeding helps
maintain or increase nutrient intake, and halt or reverse
weight loss. It is not indicated in the prophylaxis of cardiac
cachexia. Although no data from large clinical trials regarding
the effect of enteral nutrition on cachexia in chronic heart
failure are currently available, the physiological arguments
lead to absolute consensus [33].
In the ﬁght against catabolism, optimal nutrition cannot be
separated from physical activity. According to some reports,
rehabilitation is just another non-pharmacological modality to
improve a patient's overall status, increase exercise tolerance
and maximum oxygen uptake, improve NYHA functional class
and, possibly decrease mortality. Rehabilitation including
exercise testing should be initiated under professional
supervision. The recommendation is to start with light
continuous endurance training to be later combined with
interval resistance training [34–36]. However, the well
designed large HF-ACTION study documented only a mild
reduction in mortality and re-hospitalization rates [37]. Still,
consistent with the guidelines of the Czech and European
Societies of Cardiology, a reasonable level of supervised
physical activity in the earlier stages of the disease is only
advisable if the patient enjoys a better quality of life.
Sleep-related difﬁculty breathing (central or obstructive
sleep apnea) is a relatively frequent ﬁnding in chronic heart
failure patients [38,39]. This comorbidity should also be
considered as effective therapy that can again appreciably
improve one's quality of life.
The issue of implantable cardioverter/deﬁbrillator (ICD)
deactivation continues to be the most difﬁcult and controver-
sial one. In patients receiving predominantly palliative care in
end-stage heart failure, the ICD should be deactivated [40]. The
patient and their family should be advised over time and
gently that, under certain circumstances, anti-arrhythmic
therapy may in fact only prolong the suffering associated with
the dying process. At the same time, they should be assured
that ICD deactivation will not result in sudden death.
Nevertheless, the ﬁnal decision must be made by the
particular, well-informed, and competent patient. Several
reports have suggested some patients may be reluctant to
have the device deactivated or try to delegate decision-making
to their physician [41]. These issues should be discussed
relatively early, ideally at a time when the patient is not yet
confronted with impending death. There is no doubt ICD
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 9 – e 4 4 e43deactivation should be considered in cases where the patient
is clearly dying, has signed informed consent for a do-not-
resuscitate (DNR) order, or the quality of life is so poor that
sudden cardiac death can in fact be perceived as some sort of
liberation [13]. In patients receiving cardiac resynchronization
therapy (CRT), it is preferred to let the device–given its
signiﬁcant beneﬁcial symptomatic effect–work until the end
of life.
Psychological and spiritual needs
The psychological burden building up as the patient sees their
overall health steadily decline is one of the main causes of
deteriorating quality of life [31]. Not infrequently, chronic
heart failure patients develop a depressive illness with a
prevalence of more than 20%, and the ﬁgure rises as NYHA
class increases. Some authors have suggested it is yet another
independent factor increasing mortality [42,43]. While hard
data showing an association between antidepressant therapy
and reduced mortality are unavailable, drug therapy and
psychotherapy may improve the quality of life.
As spiritual satisfaction and acceptance of the life situation
as it is are clearly associated with a lower incidence of
depression and better quality of life [44], the physician should
seek to learn more about the spiritual needs of the patient
whatever their denomination, and support the patient in this
area. In cases where the physician feels incompetent and ﬁnds
it uneasy, this task should be undertaken by another member
of the multidisciplinary team.
Conclusion
Palliative care is a critical component of care provided to
patients with advanced chronic heart failure. These
approaches are intended to improve the quality of life of
patients and their families in cases of refractory symptoms
through early identiﬁcation and intervention in physical,
psychological, social, as well as spiritual terms. Palliative care
poses a major challenge for all members of teams providing
comprehensive care to this patient population not only during
the ﬁnal weeks of their life.
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